Balance Sheet Dive: Sage Therapeutics Inc (SAGE)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $7.50 in the prior trading day, Sage Therapeutics Inc (NASDAQ: SAGE) closed at $7.44, down -0.80%. In other words, the price has decreased by -$0.80 from its previous closing price. On the day, 0.65 million shares were traded. SAGE stock price reached its highest trading level at $7.59 during the session, while it also had its lowest trading level at $7.28.

Ratios:

Our goal is to gain a better understanding of SAGE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.95 and its Current Ratio is at 9.95. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, TD Cowen on July 30, 2024, Downgraded its rating to Hold and sets its target price to $10 from $16 previously.

On July 25, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $18 to $12.

On May 29, 2024, Robert W. Baird started tracking the stock assigning a Neutral rating and target price of $15.Robert W. Baird initiated its Neutral rating on May 29, 2024, with a $15 target price.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SAGE now has a Market Capitalization of 457878432 and an Enterprise Value of -191166896. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.67 while its Price-to-Book (P/B) ratio in mrq is 0.72. Its current Enterprise Value per Revenue stands at -1.966 whereas that against EBITDA is 0.427.

Stock Price History:

Over the past 52 weeks, SAGE has reached a high of $28.26, while it has fallen to a 52-week low of $7.43. The 50-Day Moving Average of the stock is -23.88%, while the 200-Day Moving Average is calculated to be -54.36%.

Shares Statistics:

The stock has traded on average 1.01M shares per day over the past 3-months and 658110 shares per day over the last 10 days, according to various share statistics. A total of 60.04M shares are outstanding, with a floating share count of 50.28M. Insiders hold about 17.64% of the company’s shares, while institutions hold 88.63% stake in the company. Shares short for SAGE as of 1723680000 were 5930174 with a Short Ratio of 5.84, compared to 1721001600 on 5570687. Therefore, it implies a Short% of Shares Outstanding of 5930174 and a Short% of Float of 11.01.

Most Popular